- Datum20.01.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Nkarta Inc. Registered Shares DL -,0001 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Nkarta Inc. Registered Shares DL -,0001 Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,95 %
Intraday
10,00 %
1 Woche
11,17 %
1 Monat
12,97 %
Seit Jahresbeginn
-11,06 %
1 Jahr
-62,54 %
3 Jahre
-96,13 %
5 Jahre
Passender Service zu Nkarta Inc. Registered Shares DL -,0001
Webinar zu Nkarta Inc. Registered Shares DL -,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,310-2,740
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Nkarta Inc. Registered Shares DL -,0001
Keine Dividenden verfügbar
Termine von Nkarta Inc. Registered Shares DL -,0001
Keine aktuellen Termine
Beschreibung
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
